Skip to main content
OpenTrials
Completed

NCT Number: NCT00302302

The Effects of L-arabinose on Intestinal Sucrase Activity in Man

The purpose of this study is to investigate the effect of L-arabinose in a sugar-rich meal on intestinal sucrase activity in healthy volunteers by measuring postprandial blood glucose and insulin, and selected intestinal hormonal responses to increasing doses of L-arabinose.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–30 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Institute of Human Nutrition, The Royal Veterinary and Agricultural University

Frederiksberg, DK-1958, Denmark

About this study

Background:

The intake of common table sugar (sucrose) in the industrialised countries is relatively high. In Denmark the daily intake of sugar is in the range of 30-40 g/d exclusive the intake of sugar containing drinks. The health consequences of this relatively high sugar intake are heavily debated in the media. One of the arguments is that a high sugar intake may be one of the factors involved in the development of the metabolic syndrome, including overweight, increased blood glucose and insulin levels as well as impaired insulin action.

L-arabinose is widely distributed in plants and is a common component in plant cell walls in maize, wheat, rye, rice, plant gums etc. The isolated 5-carbon sugar has been shown to suppress the increase of blood glucose and plasma insulin after ingestion of sucrose in rats by inhibition of sucrase activity. In vitro studies on Caco-2 cells indicate that L-arabinose is a potent inhibitor on sucrase activity, possibly in a non-competitive way.

Potential nutritional advantages of consuming L-arabinose in combination with sucrose may therefore be a delayed digestion of sucrose and a lower absorption of glucose, resulting in both lower blood glucose and insulin levels. A delayed digestion of sucrose will reduce the energy utilisation with the potential of reducing weight gain in human subjects.

Methods:

This dose-response study with 14 healthy male volunteers has a randomised cross-over design based on four single "meals" separated by one week wash-out periods. Sugar rich drinks supplemented with different doses of L-arabinose will be tested with respect to postprandial blood glucose, insulin, triglyceride, glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1). Postprandial blood samples will be taken every 15 to 30 min for 180 min. Appetite sensations will be measured every 30 min during the experiment. After 180 minutes a lunch will be served and energy intake (EI) will be registered.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • healthy males
  • BMI between 18.4-25 kg/m2
  • age between 18 and 30

Exclusion criteria

  • donation of blood 3 months before or during the study
  • gastrointestinal disorders, diabetes, hypertension, hyperlipidemia, chronic infectious disease (HIV or hepatitis)
  • smoking
  • consumption of more than 21 alcoholic drinks/week
  • elite athletes
  • on medication

Treatment and study plan

L-arabinose

Drug

Primary outcomes

  1. Plasma glucose, insulin, triglycerides, GIP and GLP-1

    Time frame: 2 hours

    Blood samples 2 hours after a test meal

Secondary outcomes

  1. Appetite measurements and energy intake

    Time frame: 10 hours

    measured after a test meal

Sponsors and collaborators

Lead sponsor

University of Copenhagen

Other

Collaborators

  • Danisco

Registry information

Official study title

The Effects of Increasing Doses of L-arabinose in a Sucrose Rich Meal on Intestinal Sucrase Activity in Man

Important dates

Study start
2005
Primary completion
2005
Study completion
2006
First posted
Mar 14, 2006
Registry last updated
Feb 26, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.